Caris Life Sciences (CAI) Return on Invested Capital (2026)
Caris Life Sciences' (CAI) quarterly Return on Invested Capital came in at 2.11% in Q1 2026.
Caris Life Sciences (CAI) Return on Invested Capital (2026) Analysis & Trends
Caris Life Sciences' Return on Invested Capital history runs 1 years deep, the most recent figure standing at 2.11% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Caris Life Sciences | 4.42 Bn | 3.60 Bn | 214.23 Mn | 2.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.11% |